CoChat

Effectiveness of CoronaVac in children 3–5 years of age during the SARS-CoV-2 Omicron outbreak in Chile

Open access
Jara, Alejandro, Undurraga, Eduardo A., Zubizarreta, José R., González, Cecilia, Acevedo, Johanna, Pizarro, Alejandra, Vergara, Verónica, Soto-Marchant, Mario, Gilabert, Rosario, Flores, Juan Carlos, Suárez, Pamela, Leighton, Paulina, Eguiguren, Pablo, Ríos, Juan Carlos, Fernandez, Jorge, García-Escorza, Heriberto, Araos, Rafael · 2022 · Nature Medicine
Cited by 100

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

The outbreak of the B.1.1.529 lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Omicron) has caused an unprecedented number of Coronavirus Disease 2019 (COVID-19) cases, including pediatric hospital admissions. Policymakers urgently need evidence of vaccine effectiveness in children to balance the costs and benefits of vaccination campaigns, but, to date, the evidence is sparse. Leveraging a population-based cohort in Chile of 490,694 children aged 3–5 years, we estimated the effectiveness of administering a two-dose schedule, 28 days apart, of Sinovac’s inactivated SARS-CoV-2 vaccine (CoronaVac). We used inverse probability-weighted survival regression models to estimate hazard ratios of symptomatic COVID-19, hospitalization and admission to an intensive care unit (ICU) for children with complete immunization over non-vaccination, accounting for time-varying vaccination exposure and relevant confounders. The study was conducted between 6 December 2021 and 26 February 2022, during the Omicron outbreak in Chile. The estimated vaccine effectiveness was 38.2% (95% confidence interval (CI), 36.5–39.9) against symptomatic COVID-19, 64.6% (95% CI, 49.6–75.2) against hospitalization and 69.0% (95% CI, 18.6–88.2) against ICU admission. The effectiveness against symptomatic COVID-19 was modest; however, protection against severe disease was high. These results support vaccination of children aged 3–5 years to prevent severe illness and associated complications and highlight the importance of maintaining layered protections against SARS-CoV-2 infection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-022-01874-4

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 100

Metadata

Authors
Jara, A., Undurraga, E. A., Zubizarreta, J. R., González, C., Acevedo, J., Pizarro, A., Vergara, V., Soto-Marchant, M., Gilabert, R., Flores, J. C., Suárez, P., Leighton, P., Eguiguren, P., Ríos, J. C., Fernandez, J., García-Escorza, H., & Araos, R.
Venue
Nature Medicine
Published
2022-05-23
Volume
28
Issue
7
Pages
1377-1380
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4281296929
Cited by
100
References
10
FWCI
10.89
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effectiveness of CoronaVac in children 3–5 years of age during the SARS-CoV-2 Omicron outbreak in Chile. https://app.cochat.ai/papers/10.1038/s41591-022-01874-4
The paper
Jara, A., Undurraga, E. A., Zubizarreta, J. R., González, C., Acevedo, J., Pizarro, A., Vergara, V., Soto-Marchant, M., Gilabert, R., Flores, J. C., Suárez, P., Leighton, P., Eguiguren, P., Ríos, J. C., Fernandez, J., García-Escorza, H., & Araos, R. (2022). Effectiveness of CoronaVac in children 3–5 years of age during the SARS-CoV-2 Omicron outbreak in Chile. Nature Medicine. https://doi.org/10.1038/s41591-022-01874-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.